NCT05798026

A Phase 1 Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of EU103 in Advanced or Metastatic Solid Tumors That Have Failed Standard Therapy

A Dose-escalation, Single-arm, Open-Label, Phase 1 Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of EU103 in an Advanced or Metastatic Solid Tumors Who Have Failed Standard Therapy

• Status: Unknown
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 15 (estimated)
• Sponsor: Eutilex · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Phase 1 (dose escalation) of this study will evaluate: The safety and tolerability of EU103 treatment are evaluated for patients with advanced or metastatic solid tumors who have failed standard therapy to determine the maximum tolerated dose and recommended Phase 2 dose. And preliminary efficacy (tumor response), The pharmacokinetic characteristics are evaluated, and changes are investigated.

Conditions

• Solid Tumor

Interventions

Type	Name	Description
DRUG	EU103	EU103 will be administered via intravenous infusion.

Timeline

• Start date: 2023-08-08
• Primary completion: 2025-04-30
• Completion: 2025-12-31
• First posted: 2023-04-04
• Last updated: 2024-03-13

Locations

3 sites across 1 country: South Korea